Efficacy of a meal sequence in patients with type 2 diabetes

RESULTS   The researchers included 230 participants in eight trials, including both trials that examined long-term changes (more than two months

New medication therapies must form part of the conversation around diabetes

We cannot turn a blind eye to the healthcare crisis we are currently facing.

Sanofi celebrates World Diabetes Day

The theme of Diabetes Day was Access to Care.

The GLP1-RA class and dulaglutide

Please note this webinar is for physicians, GPs and specialists only.

Keys to successful diabetes management in Ramadan

Ramadan is observed by Muslims worldwide as a month of fasting, prayer, reflection, and community. In 2022 the Holy month of Ramadan starts on the evening of 2 April, lasting 30 days and ending at sundown on 1 May.1

Novo Nordisk launches once-weekly semaglutide in South Africa

Once-weekly semaglutide, a human glucagon-like peptide 1 receptor agonist (GLP1-RA), was launched in South Africa on 21 August 2021.

Erectile dysfunction webinar

ED negatively impacts the quality of life, and it is recommended to screen all adult men with diabetes regularly.

Primary prevention of CVD in type 2 diabetes

Studies of new glucose-lowering therapies have a focus on primary prevention.

Metformin: the oldest, but still the best treatment for T2DM

The discovery of metformin began with the synthesis of galegine-like compounds derived from Gallega officinalis; a plant traditionally employed in Europe as a drug for diabetes treatment for centuries

Real-world data from the ARISE Study

The IDegAsp clinical trial program (BOOST) clinical investigation programme for patients with diabetes assessed the safety and efficacy of once or twice daily administration of IDegAsp using 26-week-long treat-to-target studies.

Upcoming webinar: Prevention of cardiovascular disease in type 2 diabetes

Dr Tsabedze presents on prevention of cardiovascular disease in type 2 diabetes.

Study finds antacids may improve blood sugar control in diabetics

The effects of proton pump inhibitor antacids on blood sugar control should be considered when prescribing antacids to patients with diabetes.